|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Trading: SELL @ $0.041
Signal Strength: MEDIUM
Bionomics (ASX:BNO) currently has negative momentum of -0.02 This means the current price is less than the price 14 days ago and therefore losing momentum.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement
Momentum measures the rate of change in closing prices and is used to detect trend weakness and likely reversal points. It is often underrated because of its simplicity. High Momentum readings (positive or negative) occur when a trend is at its strongest. Lower readings are found at the start and end of trends. Overbought and oversold levels are set separately for each security based on the performance of the indicator over past cycles.
Calculation: Momentum Oscillator (MOM):
1) Closing Price [today] - Closing Price [n days ago];
PROFILE: Bionomics (BNO.AX)
Stock Exchange: ASX
Ticker Codes: | BNO.AX | ASX:BNO |
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in the initiation of a Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has partnerships with Merck & Co., Inc.; Cancer Therapeutics Cooperative Research Centre; Genmab A/S; Laboratory Corporation of America (LabCorp); Athena Diagnostics; and Genetic Technologies Limited. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.
|RSG Resolute Mining||1.74||7.1||9,161,059||0.07||BULLISH|
|MLX Metals X||0.25||6.4||2,769,031||0.15||BULLISH|
|NST Northern Star Resources||13.47||6||4,840,454||0.3||BULLISH|
|OMH OM Holdings||0.86||5.5||28,581||0.3||BULLISH|
|SBM St Barbara Mines||3.55||5.3||5,019,351||0.4||BULLISH|
|AGG Anglogold Ashanti||5.56||5.1||467,306||1.74||BULLISH|
|RRL Regis Resources||6.38||4.9||5,376,386||0.16||BULLISH|
|ABC Adelaide Brighton||4.35||4.3||2,365,140||0.33||BULLISH|